247 related articles for article (PubMed ID: 19929947)
1. Targeting histone deacetylases in pancreatic ductal adenocarcinoma.
Schneider G; Krämer OH; Fritsche P; Schüler S; Schmid RM; Saur D
J Cell Mol Med; 2010 Jun; 14(6A):1255-63. PubMed ID: 19929947
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
3. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.
Schneider G; Krämer OH; Schmid RM; Saur D
J Gastrointest Cancer; 2011 Jun; 42(2):85-92. PubMed ID: 21271301
[TBL] [Abstract][Full Text] [Related]
4. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
6. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
8. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
Ouaïssi M; Giger U; Sielezneff I; Pirrò N; Sastre B; Ouaissi A
J Biomed Biotechnol; 2011; 2011():315939. PubMed ID: 20981265
[TBL] [Abstract][Full Text] [Related]
9. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
10. Targeting apoptosis pathways in pancreatic cancer.
Arlt A; Müerköster SS; Schäfer H
Cancer Lett; 2013 May; 332(2):346-58. PubMed ID: 21078544
[TBL] [Abstract][Full Text] [Related]
11. HDAC3 mediates smoking-induced pancreatic cancer.
Edderkaoui M; Xu S; Chheda C; Morvaridi S; Hu RW; Grippo PJ; Mascariñas E; Principe DR; Knudsen B; Xue J; Habtezion A; Uyeminami D; Pinkerton KE; Pandol SJ
Oncotarget; 2016 Feb; 7(7):7747-60. PubMed ID: 26745602
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
13. High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
Li H; Li X; Lin H; Gong J
Mol Med Rep; 2020 Feb; 21(2):822-832. PubMed ID: 31974610
[TBL] [Abstract][Full Text] [Related]
14. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Wang W; Gao J; Man XH; Li ZS; Gong YF
Oncol Rep; 2009 Jun; 21(6):1439-47. PubMed ID: 19424621
[TBL] [Abstract][Full Text] [Related]
15. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
17. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
Shouksmith AE; Shah F; Grimard ML; Gawel JM; Raouf YS; Geletu M; Berger-Becvar A; de Araujo ED; Luchman HA; Heaton WL; Bakhshinyan D; Adile AA; Venugopal C; O'Hare T; Deininger MW; Singh SK; Konieczny SF; Weiss S; Fishel ML; Gunning PT
J Med Chem; 2019 Mar; 62(5):2651-2665. PubMed ID: 30776234
[TBL] [Abstract][Full Text] [Related]
19. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment.
Bauden M; Tassidis H; Ansari D
Toxicol Lett; 2015 Jul; 236(1):8-15. PubMed ID: 25917448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
